palbociclib for platinum-resistant metastatic head and neck cancer
Published 6 years ago • 156 plays • Length 2:28Download video MP4
Download video MP3
Similar videos
-
2:53
positive results for palbociclib/cetuximab therapy in head and neck cancer
-
1:45
real-world clinical outcomes in metastatic breast cancer patients treated with palbociclib
-
5:04
paloma-3: palbociclib and fulvestrant for hr-/her metastatic breast cancer
-
39:21
bcfnz webinar: palbociclib (ibrance) for advanced or metastatic hr breast cancer - nz update
-
3:12
novel immunotherapy approaches in metastatic head and neck cancer
-
6:29
study of palbociclib after cdk & endocrine therapy in er /her2- metastatic breast cancer
-
1:59
potential of immunotherapy in head and neck cancer
-
3:17
the development of immunotherapies in the treatment of relapsed metastatic head and neck cancer
-
7:38
increased progression free survival for patients with metastatic head and neck cancer using afatinib
-
3:30
final results from pallas: adjuvant palbociclib in hr /her2- early breast cancer
-
1:52
esmo 2022 highlights in head and neck cancer
-
1:36
addition of an egfr/tgfβ inhibitor with pembrolizumab in head and neck cancer
-
2:55
tacti-002 and tacti-003: eftilagimod alpha for metastatic head and neck squamous cell carcinoma
-
1:22
the extreme regimen for head and neck cancer
-
3:34
2016 acs heroes of chemistry: pfizer – ibrance® for the treatment of metastatic breast cancer
-
1:19
relacorilant nab-paclitaxel in recurrent, platinum-resistant ovarian cancer
-
1:43
composite biomarkers predictive of palbociclib endocrine treatment benefit in early breast cancer
-
2:14
innovative approaches to the treatment of head and neck cancer
-
2:29
breast cancer: palbociclib in later lines